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Objective: Cardiac pacing is sometimes required for patients with congenital heart disease for various reasons.
Because of complex anatomy, repetitive previous heart surgery and patient size, epicardial leads are of special
importance in these patients. Using epicardial leads has been discussed controversly regarding pacing performance
and lead survival. The aim of this study was to review the long-term data on pacing performance as well as lead
survival of epicardial leads implanted in our center.
Methods: Retrospective chart review and review of the literature.
Results: 82 consecutive pediatric patients or adult patients with congenital heart disease with 158 epicardial leads
(Medtronic 4968, bipolar, steroid - eluting) were included. We found 1.2% pacemaker-related early postoperative
complications. The incidence of lead dysfunction was 7.5% (12/158) for primary (i.e. directly related to the lead itself)
lead dysfunction and 3.2% (5/158) of lead abandonment for reasons not directly related to the lead itself. Primary
lead dysfunction occured after a median of 3.83 years. Lead survival at 2, 5 and 10 years was 98.7%, 93% and 92.4%.
There were no infections reported. Stable median measurements for impedance (RA/RV/LV of 577/483/610 Ohm),
sensing threshold (RA/RV/LV of 2.0/11.0/10.0 mV) and pacing threshold (RA/RV/LV of 0.75 V at 0.4 ms/1.0 V at
0.49 ms/1.0 V at 0.45 ms) indicated a good mid- to longterm performance. The only risk factor for primary lead
dysfunction was young age at implantation.
Conclusion: The use of epicardial leads in pediatric and adult patients with congenital heart disease shows good
longterm outcomes in terms of pacing performance and lead survival. The authors encourage using epicardial leads
in patients with congenital heart disease based on the patient‘s individual characteristics.
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Cardiac pacing is required rather frequently in patients
with congenital heart disease (CHD) for various reasons,
ranging from symptomatic bradycardia caused by sinus
node dysfunction over postoperative complete heart
block to cardiac resynchronization therapy. Although
transvenous implantation of a cardiac pacemaker is tech-
nically feasible and less invasive than surgical place-
ment of epicardial leads, there are several advantages* Correspondence: christian.paech@med.uni-leipzig.de
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with CHD. Most congenital heart disease patients will
need cardiac pacing throughout their whole life. In view
of the limited lead survival both in epicardial and endo-
cardial leads, as well as the necessary relocation of the
leads due to the natural growth of children, these patients
expect lead removal and reimplantation several times in
their lives [1]. Some of these patients require repetitive
surgical procedures and cardiac catheterizations for other
reasons than pacemaker implantation. It seems of utmost
importance to save venous access taking into account
hemodynamics and future catheter or transvenous pacing
lead placement in those patients. In addition, it is relativelytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cardial leads during cardiac surgery of the underlying
congenital heart disease. As recent data support, epi-
cardial pacing provides the possibility for left apical
pacing. Left apical pacing is reported as the superior
pacing site in view of pacing induced dyssynchrony
[2]. In infants and neonates epicardial lead placement
leaves the possibility for abdominal device implan-
tation which provides enough room to host sufficient
wire reserve to match the child’s growth and serves as
bridge to a transvenous pacemaker system at an older
age, when the risk for venous occlusion, thrombosis or
impairment of venous flow is lower.
In this cohort the patients can be assigned to one of
four main groups requiring pacemaker implantation.
The first group consists of children with congenital heart
disease after surgical procedures, for either repair or pal-
liation with surgical induced complete heart block. The
second group includes patients who suffer from congeni-
tal anatomic cardiac malformation like corrected con-
genital transposition of the great arteries, heterotaxia or
atrial isomerism resulting in sinus node dysfunction or
complete heart block. The third group contains those
patients with intraventricular or interventricular dyssyn-
chrony who require pacing for cardiac resynchroniza-
tion, whereas the fourth group includes patients without
structural heart disease and complete heart block or
asystole during breath-holding spells.
The aim of this study was to evaluate the mid- to
longterm lead survival and performance in these spe-
cial groups of patients and to review the literature




The data of 82 consecutive patients who were either
implanted or looked after at the division of pediatric car-
diology, University of Leipzig, Heart Center, were evalu-
ated retrospectively. Included were all patients who
received a permanent pacemaker system with epicardial
leads, either atrial or ventricular from 1996 to 2010. In-
clusion required at least one structured follow-up per-
formed for at least one time after implantation and at
least 1 month after implantation. Follow-up contained a
12-lead ECG, a device interrogation with measurement
of thresholds, sensing and lead impedance, chest x-ray,
physical examination and the patient’s history. Patients
with an ICD and patients with unipolar pacemaker leads
(n = 2) were excluded from this study. The collected data
were reviewed by two experienced pediatric cardiolo-
gists, one of them specialized in pediatric heart rhythm
and device therapy. The review included the surgical re-
port and all available follow-up data. Whenever a patientreceived follow-up at another center, the structured
follow-up concerning lead data ended. However, further
information concerning lead complications was obtained
from those patients.
Definitions
Lead dysfunction was differentiated in primary dysfunc-
tion and lead abandonment. Primary lead dysfunction
included problems directly related to the lead itself such
as exit block due to lead fracture, isolation defects or
dislocation. Lead abandonment included reasons not dir-
ectly related to the lead itself such as infection, elective
replacement for other reasons or dislocation by an exter-
nal trauma.
Statistics
Data analysis was performed using IBM SPSS 20.0 Soft-
ware. Patients were compared using Student t-test or
Mann–Whitney test for continuous variables and chi-
square test or Fisher’s exact test for binary variables. The
Fisher exact test was utilized in place of chi-square test
when the expected frequency of a cell within a contin-
gency table was <5. Kaplan – Meier plots were used to
illustrate lead survival. A p-value of < 0.05 was consid-
ered statistically significant. All electrode measurements
are depicted as median with standard deviation. The sur-
vival data are depicted as median with range.
Results
Patients characteristics
82 patients meeting all inclusion and no exclusion cri-
teria were identified. This accounted for 158 epicardial
pacemaker leads (Medtronic 4968, bipolar, steroid - eluting
n = 158). All leads were connected to a standard cardiac
pacemaker device of one of the following companies:
Medtronic Inc., Biotronik or St. Jude Medical. All patients
were treated perioperatively with cephazoline (50 mg/kg
every 8 h) for at least 24 h, mostly until central venous
lines were removed.
61 patients suffered from congenital heart disease,
while 21 patients showed anatomically normal hearts.
There were 42 female and 40 male patients with a me-
dian age of 7.64 years (range 1.08 – 54.7) and a median
age at primary implantation of a cardiac pacemaker de-
vice of 1.95 years (range 0.01 – 48.5). Median time of
follow-up was 3.3 years (range 0.1 – 15.2).
Indication
Indications for lead implantation were postoperative
complete heart block in 33 patients, sick sinus syndrome
in 19 patients, congenital complete heart block in 14 pa-
tients, complete heart block in association with corrected
congenital transposition of the great arteries in 9 patients,
breath-holding spells in 5 patients and 2 patients received
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nization therapy. Indications are depicted in Table 1.
Mortality rate
There was no death related to a dysfunction of either
the cardiac pacemaker device or a lead dysfunction.
Early complications
Reviewing all 82 patients, only one (1.2%) pacemaker-
related postoperative complication was reported. The af-
fected patient had to undergo surgical revision due to a
pocket hematoma.
Late complications
Two cases of coronary compression during follow-up
occured. Both patients required re-operation with repo-
sitioning of the epicardial pacing leads. The first patient
was a female infant with congenital complete heart block
caused by maternal lupus erythematodes who underwent
implantation of epicardial VVI pacemaker at the age ofTable 1 Indication groups for cardiac pacing




(% of all 82 patients)
Congenital heart block 23 (28)









Subaortic stenosis 1 (1)
Arterial switch 5 (6)
Tetralogy of Fallot 1 (1)
others 11 (14)
Sick sinus syndrome 19 (24)
uncorrected CHD 3 (4)
Heterotaxia 2 (3)







Pacing induced 1 (1)
End stage CHD 1 (1)
Breath holding spells 5 (6)
The left column shows the indication groups for cardiac pacing. The middle
column shows the surgical procedures or main congenital anomalies of each
indication group. The right column shows the number of patients per indication
group (bold figures) and number of patients per surgical procedure or main
congenital anomaly within each indication group.3 months and received an additional atrial epicardial
electrode at the age of 1.75 years. Four months later, she
developed dilative cardiomyopathy and was listed for
cardiac transplantation. Selective angiography of the left
coronary artery revealed cardiac strangulation caused by
the right ventricular electrode. Compression of the left
anterior descending artery and circumflex artery was re-
lieved by repositioning the right ventricular electrode. A
left ventricular electrode and a biventricular pacemaker
were inserted for resynchronization therapy. On dis-
charge, the interventricular synchrony was improved.
Despite the intial improvement she developed spastic
tetraparesis one month after dismissal and died 9 month
later due to non-cardiac reasons.
The second patient was an 8-year-old boy with complex
congenital malformation, including a left atrial isomerism,
polysplenia, sick sinus syndrome and anomalous venous
drainage via a prominent vena azygos. Intracardiac lesions
consisted of a ventricular septal defect, a common atrium
and a non- compaction of the apical left ventricle. Pace-
maker implantation had been performed at the age of
5 days. Chest x-ray showed an anomalous course of the
epicardial RV pacemaker lead forming a loop around the
left ventricle causing a diastolic LV constriction (Figure 1).
Cardiac catheterization showed compression of the cir-
cumflex artery. In the absence of impaired left ventricular
wall motion, negative troponine and no signs of myocar-
dial ischemia, the pacemaker lead was exchanged for a
new epicardial two chamber device. The old lead was cut
off. The patient did well during follow up. Both patients
had received primary pacemaker implantation at another
hospital. In summary, cardiac strangulation is a rare com-
plication of epicardial pacing [3].
Lead failure
The incidence of primary lead dysfunction was 7.5%
(12/158). The incidence of lead abandonment was 3.2%
(5/158). The reason for primary lead dysfunction was al-
ways lead fracture (n = 12). No case of isolation defect or
macrodislocation was reported. Lead abandonment was
always due to lead removal for non-pathologic circum-
stances such as reoperation of the underlying congenital
heart disease (n = 5). It is of some importance that no in-
fections were reported in this study group. Lead survival
at 2, 5 and 10 years was 98.7%, 93% and 92.4%. Primary
lead dysfunction occured after a median of 3.83 years
(range 0.78 – 6.12) (Figure 2). Primary lead dysfunction
was not correlated to any of the following variables;
(1) sex (p = 0.12); (2) structural normal heart versus con-
genital heart disease (p = 0.49); (3) lead position seperated
into right ventricular apex, right ventricular free wall,
right ventricular outflow tract, left ventricular apex or left
ventricular free wall (right ventricular positions p = 0.62,
left ventricular positions p = 1.0); (4) or to the presence
Figure 1 Shows the chest x-ray of the second patient with cardiac strangulation by an epicardial pacemaker lead. (For details read
Results). A: Chest x-ray a.p. projection. B: Lateral projection showing the abnormal course of the RV lead, which forms a loop around the left ven-
tricle. Note the course of the lead within the border of the heart shadow in panel B.
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primary lead dysfunction was significantly more frequent
in patients who had received implantation at younger age
(p = 0.01).
Thresholds and impedance
Pacing thresholds, sensing and impedance measure-
ments at initial interrogation following implantation andFigure 2 Depicts a Kaplan-Meier curve of lead survival. Starting with 1
primary lead dysfunction or lead abandonment.at the patients last follow-up after a mean of 3.3 years
(range 0.1 – 15.2) are depicted in Table 2.
Discussion
This study reports on the single center experience with
158 Medtronic 4968, bipolar, steroid - eluting epicardial
cardiac pacemaker leads in 82 pediatric and adult patients
with CHD.58 pacemaker leads, every step down of the curve marks a case of
Table 2 Lead data at primary implantation and follow-up
Pacing PI Sensing PI Impedance PI Pacing FUP Sensing FUP Impedance FUP
RA/LA 0,9 V (0,47 – 1,67), at
0,4 ms (0,31 – 0,5)
2,8 V (0,81 – 4,8) 593 Ω (410 – 776) 0,75 V (0,12 – 1,38), at
0,4 ms (0,28 – 0,52)
2,0 V (0,3 – 8,0) 577 Ω (274 – 1256)
RV 0,9 V (0,48 – 1,32), at
0,49 ms (0,34 – 0,64)
9,2 V (3,0 – 15,4) 594 Ω (245 – 913) 1,0 V (0,38 – 4,2), at
0,49 ms (0,27 – 0,7)
11,0 V (6,16 – 15,8) 482 Ω (273 – 886)
LV 0,75 V (0,25 – 1,48), at
0,5 ms (0,36 – 0,64)
9,5 V (6,6 – 18) 717 Ω (311 – 1123) 1,0 V (0,27 – 1,73), at
0,45 ms (0,24 – 0,66)
10,0 V (4,73 – 15,27) 610 Ω (463 – 757)
Table 2: RA = right atrium, LA = left atrium, RV = right ventricle, LV = left ventricle, PI = primary implantation, FUP = last follow-up.
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survival of 93% to 99% and 5 year survival of 58% to
89% respectively for epicardial leads. Lead failure in epi-
cardial leads is reported from 8% to 36% with a wide
range between centers [4-7]. As stated by Post et al.,
who reviewed data of 93 patients with congenital heart
disease in a single center focussing on possible risk fac-
tors for lead failure, only young age at implantation
proved to be a risk factor for lead dysfunction [8]. Inter-
estingly, Murayma et al. found congenital heart disease
itself to be the only predictor of lead failure in their col-
lective of 109 pediatric patients [9].
Two single center studies investigating advantages of
endocardial over epicardial leads, were carried out.
Odim et al. found 18% versus 10% of lead dysfunction
comparing epicardial to endocardial leads in 148 pediatric
patients, whereas Fortescue et al. found 9% versus 7% of
lead dysfunction comparing epicardial to endocardial leads
[10,11]. Fortescue et al. also found that acute dislodge-
ments, fractures and insulation breaks were more com-
mon in the transvenous leads group and high thresholds,
chronic dislodgements and infections were more common
in the epicardial leads group. In contrast, Odim et al. re-
ported no significant differences in performance and lead
survival between these groups.
By taking a closer look at the currently available data
on the Medtronic 4968 epicardial steroid-eluting lead,
Tomaske et al. reported the largest pediatric series with
114 children with 239 atrial and ventricular bipolar
epicardial leads (Medtronic CapSure 10366 or 4968,
Minneapolis, MN) enrolled. After a follow-up of up to
12.2 years (median, 3.2 years) they found low median
pacing thresholds below 1.2 V at 0.5 ms and a lead sur-
vival of 85% at 5 years for atrial and 94% for ventricular
leads respectively. They concluded that bipolar steroid-
eluting leads provide an alternative approach for perman-
ent pacing and may also be considered for left atrial
and ventricular pacing, resynchronization, or defibrillator
therapy.
In summary, the results in the presented study are
consistent with the findings in previous studies. Good
mid- to even longterm survival of epicardial leads as well
as stable pacing thresholds, lead impedance and sensing
capacity were ascertained. In comparison to other studygroups, this study reported a rather low incidence of
lead dysfunction of 7.5%. Reasons for this may be based
on the implanting cardiac surgeon’s individual experi-
ence as well as the exclusive use of bipolar steroid elut-
ing leads in contrast to unipolar or non drug eluting
pacing leads. The only risk factor for primary lead dys-
function in this study group proved to be young age at
implantation. Taking a closer look at the affected pa-
tients, nearly all of them were between 3 and 7 years of
age at the time of lead dysfunction. Patients of this par-
ticular age group typically show a high degree of natural
growth and physical activity. It may be speculated that
this natural behavior, possibly causing many incidental
injuries, might influence lead survival more than in older
or much younger patients. It has to be mentioned that
we found no patient at all with a device infection in the
presented study group.
In conclusion, most studies conducted on this topic
found that modern, i.e. steroid-eluting bipolar epicardial
pacemaker leads show good long term performance and
durability [12,13]. The currently available data concern-
ing advantages and disadvantages of endocardial versus
epicardial pacemaker leads remain contradicting. As the
only concurrent finding, both single center comparisons
mentioned above, found a lower rate of lead failure in
the endocardial leads group. However, in both studies
patients who received epicardial lead implantation were
younger, more often affected by congenital heart disease
and showed a higher rate of concomittant surgery, which
might have caused the negative results in the epicardial
leads group. In addition, referring to the data presented
in the actual study, we report an equally low rate of lead
dysfunction as Fortescue et al. and an even lower rate
than Odim et al..
As there currently available data imply an equal per-
formance, the decision on whether to implant either
endo- or epicardial leads should rather be made on the
basis of the patient’s individual characteristics than on
technical aspects such as lead performance or durability.
Moreover, preservation of vascular access, expected op-
erations or reoperations and the spacial considerations
for leaving a pacing lead reserve to compensate the
patient’s growth should be particularly taken into ac-
count when choosing an acceptable route for pacemaker
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tients with CHD [14]. In the authors’ opinion, current
indications for epicardial leads are contraindications for
transvenous lead placement such as limited venous ac-
cess, repetitive infections of a transvenous system, small
body size, intracardiac shunt or practial reasons for ex-
ample expected cardiac surgery of the underlying con-
genital heart disease. Lately, favourable results in terms
of preservation of ventricular function were reported
for epicardial pacing from the left ventricular apex [15].
In all other patients, the less risky transvenous implan-
tation route should be preferred.
Conclusion
The use of bipolar steroid- eluting epicardial leads in the
setting of pediatric and adult patients with congenital
heart disease shows good longterm outcomes as far as
pacing performance and lead survival are concerned. In
addition, venous access is preserved for future interven-
tions and the risk for thrombosis and infection is lower.
The authors encourage using epicardial leads in patients
with congenital heart disease and other pediatric patients
based on the patient’s individual characteristics.
Limitations
Three limitations to this study have to be mentioned. First
of all, this is a retrospective study. Secondly, the presented
data are a single center experience which might be biased
due to surgical technique and internal processes. The third
limitiation is due to the fact that some patients are reffe-
renced to our center exclusively for pacemaker implan-
tation and will be looked after in a private practice. Those
patients will be presented to our centre again only in case
of a complication. Although those patients are surely with-
out pacemaker related complications, there is no struc-
tured follow-up data available.
Consent
Written informed consent was obtained from the patient
for publication of both case reports and accompanying
images.
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